Last reviewed · How we verify
Seizures in Neurosurgery — Treatment Landscape & Competitive Intelligence
3 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Cerebyx | FOSPHENYTOIN | Pfizer | Anti-epileptic Agent | Sodium channel protein type 5 subunit alpha | 1996-01-01 | |
| Phenytoin Sodium | PHENYTOIN | Viatris | Anti-epileptic Agent | Sodium channel protein type 2 subunit alpha | 1953-01-01 | |
| Dilantin | Phenytoin Sodium | Pfizer | phenytoin | Nuclear receptor subfamily 1 group I member 3 | 1953-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Pfizer · 2 drugs in Seizures in Neurosurgery
- Viatris · 1 drug in Seizures in Neurosurgery
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Seizures in Neurosurgery:
- Seizures in Neurosurgery treatment updates — RSS
- Seizures in Neurosurgery treatment updates — Atom
- Seizures in Neurosurgery treatment updates — JSON
Cite this brief
Drug Landscape (2026). Seizures in Neurosurgery — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/seizures-in-neurosurgery. Accessed 2026-06-10.
Related
- Seizures in Neurosurgery full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing